Skip to main content

Table 3 Results from current studies of EGFR-TKI efficacy on ADSC

From: The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies

Study No. of patients Ethnicity Stage Gender Smoking status EGFR activating mutation Type of TKI DCR (%) PFS (m) OS (m)
I-IIIA ≥ IIIB Male Female No Yes Positive Negative
Song et al., 2013 [17] 49 Asia N/A 53.1% (26/49) 46.9% (23/49) 26.5% (13/49) 73.4% (36/49) 33.30% (7/21) 66.7% (14/21) Gefitinib/ Erotinib 65.3% (32/49) 4.3 (2.1 for EGFR-; 8.7 for EGFR+) 17.6
Fan et al., 2017 [30] 27 Asia 85.2% (23/27) 14.8% (4/27) 40.7% (11/27) 59.3% (16/27) 74.1% (20/27) 25.9% (7/27) 100% (27/27) 0% (0/27) N/A 74.1% (20/27) 15 39
Zhang et al., 2018 [28] 148 Asia 100% (148/148) 0% (0/148) 70.7% (102/148) 29.3% (46/148) 42.6% (63/148) 57.4% (85/148) 20.2% (30/148) 79.8% (118/148) Gefitinib/ Erotinib 76.7% (23/30) N/A 43
  1. DCR Disease control rate, PFS Progression free survival, OS Overall survival, N/A Not applicable, TKI Tyrosine kinase inhibitor, EGFR- EGFR activating mutation negative, EGFR+ EGFR activating mutation positive